Advanced Scientifics and Chemic Laboratories Announce Joint Cooperation Agreement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advanced Scientifics and Chemic Laboratories Announce Joint Cooperation Agreement



Advanced Scientifics (ASI) and Chemic Laboratories reported a three-year joint cooperation agreement that will allow the two companies to collaborate on several product development projects in the pharmaceutical and biopharmaceutical markets, particularly in the areas of leachable and extractable analytical data supporting single-use systems (SUS).

The cooperation model between the two companies will consist of ASI developing film products and SUS systems for pharmaceutical and biopharmaceutical customers, while Chemic uses analytics to provide extractable data assessing material compatibility with model bioprocessing solutions.

Source: Advanced Scientifics

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here